icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections
Seattle, Washington
March 4-7, 2019
Back grey_arrow_rt.gif
High Level of Preexisting NRTI Resistance Prior
to Switching to B/F/TAF: Study 4030
  Reported by Jules Levin
CROI 2019 March 4-7 Seattle
R Acosta, M Willkom, K Andreatta, H Liu, R Martin, S Chang, H Martin, S Collins, and KL White Gilead Sciences, Inc., Foster City, CA, USA 







a. 3 participants from resistance category 3 had no post-baseline on-treatment data and were not included in this analysis
b. 5 participants had HIV-1 RNA ≥ 50 copies/ml at their last measurement in this analysis: 1 category 1 participant-59 copies/mL and later resuppressed; 1 category 2 participant-120 copies/mL and later resuppressed; 3 category 3 participants-205 copies/mL and later resuppressed; 357 copies/mL; and 25100 copies/mL. Those with ≥ 200
copies/mL were included in the resistance analysis population if they did not resuppress c. Of the 81 participants with M184V or M184I, 71 had M184V, 6 had M184I, and 4 had M184V/I